日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Challenges and Potential Solutions to Advance Global Cancer Drug Development

推进全球癌症药物研发的挑战与潜在解决方案

Glasmacher, Axel; Lyerly, Kim; Wolf, Birgit; Zapella, Pio; Zielinska, Lidia; Clark, Emma; Mauer, Murielle; Paiva, Bruno; Schiel, Anja; Sweeney, Fergus; Uyl-de Groot, Carin A; von Lilienfeld-Toal, Marie; Verweij, Jaap

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

欧洲新注册抗癌药物获取途径不均可能导致患者寿命损失。

Uyl-de Groot, Carin A; Heine, Renaud; Krol, Marieke; Verweij, Jaap

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial

新辅助化疗联合区域性热疗对局部高危软组织肉瘤患者长期预后的影响:EORTC 62961-ESHO 95 随机临床试验

Issels, Rolf D; Lindner, Lars H; Verweij, Jaap; Wessalowski, Rüdiger; Reichardt, Peter; Wust, Peter; Ghadjar, Pirus; Hohenberger, Peter; Angele, Martin; Salat, Christoph; Vujaskovic, Zeljko; Daugaard, Soeren; Mella, Olav; Mansmann, Ulrich; Dürr, Hans Roland; Knösel, Thomas; Abdel-Rahman, Sultan; Schmidt, Michael; Hiddemann, Wolfgang; Jauch, Karl-Walter; Belka, Claus; Gronchi, Alessandro

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

晚期肉瘤试验中的替代终点:一项荟萃分析

Savina, Marion; Litière, Saskia; Italiano, Antoine; Burzykowski, Tomasz; Bonnetain, Franck; Gourgou, Sophie; Rondeau, Virginie; Blay, Jean-Yves; Cousin, Sophie; Duffaud, Florence; Gelderblom, Hans; Gronchi, Alessandro; Judson, Ian; Le Cesne, Axel; Lorigan, Paul; Maurel, Joan; van der Graaf, Winette; Verweij, Jaap; Mathoulin-Pélissier, Simone; Bellera, Carine

Evaluation of patient enrollment in oncology phase I clinical trials

评估肿瘤学 I 期临床试验中的患者入组情况

van der Biessen, Diane A J; Cranendonk, Merlijn A; Schiavon, Gaia; van der Holt, Bronno; Wiemer, Erik A C; Eskens, Ferry A L M; Verweij, Jaap; de Jonge, Maja J A; Mathijssen, Ron H J

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development

创造公平的竞争环境:使生物标志物和分子诊断的开发达到药物开发的标准

Poste, George; Carbone, David P; Parkinson, David R; Verweij, Jaap; Hewitt, Stephen M; Jessup, J Milburn

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

对伊马替尼治疗失败后胃肠道间质瘤患者的舒尼替尼随机、安慰剂对照 III 期试验进行完整的纵向分析

Demetri George D, Garrett Christopher R, Schöffski Patrick, Shah Manisha H, Verweij Jaap, Leyvraz Serge, Hurwitz Herbert I, Pousa Antonio Lopez, Le Cesne Axel, Goldstein David, Paz-Ares Luis, Blay Jean-Yves, McArthur Grant A, Xu Qiang Casey, Huang Xin, Harmon Charles S, Tassell Vanessa, Cohen Darrel P, Casali Paolo G

Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design

将分子靶向药物治疗推向个性化医疗:与临床试验设计相关的问题

Verweij, Jaap; de Jonge, Maja; Eskens, Ferry; Sleijfer, Stefan

Tumor volume as an alternative response measurement for imatinib treated GIST patients

肿瘤体积可作为伊马替尼治疗胃肠道间质瘤患者的替代疗效评价指标

Schiavon, Gaia; Ruggiero, Alessandro; Schöffski, Patrick; van der Holt, Bronno; Bekers, Dave J; Eechoute, Karel; Vandecaveye, Vincent; Krestin, Gabriel P; Verweij, Jaap; Sleijfer, Stefan; Mathijssen, Ron H J

Effects of methimazole on the elimination of irinotecan

甲巯咪唑对伊立替康清除的影响

van der Bol, Jessica M; Visser, Theo J; Loos, Walter J; de Jong, Floris A; Wiemer, Erik A C; van Aken, Maarten O; Planting, Andre S; Schellens, Jan H; Verweij, Jaap; Mathijssen, Ron H J